CMH SCIENTIFICTOPOLAI · DECISION CONTROLLER
ORCHESTRATION VIEW

TopolAI

Returns a decision rather than a score: use it, keep going, acquire selectively, change the measurement, add a modality, reacquire, or abstain.

current decision
CONTINUE_SELECTIVELY

Keep the current observer and structural representation; acquire the tested added information only in pre-identified ambiguous regions, then reassess.

CMH GUARDexecution gate: ALLOW / review destination separately
NPISWhat does the substrate distinguish?UNRESOLVED SUBSET
Material local branching remains.
OptiCeilHow much is recoverable?NEAR FRONTIER
Little model-only headroom in tested representation.
TotemicAIWhat structure must persist?COHERENT
Sparse landmarks remain stable.
AcquireWhat tested observation adds value?CONCENTRATED VALUE
Added measurement helps selected regions.
ControllerWhat should happen now?ACT
Acquire selectively, then loop.
Try decision states
RESULT

Return an explicit action state, not only a score.

EVIDENCE

Preserve component-specific evidence so one metric cannot overrule the others silently.

BOUNDARIES

No automatic proof of mechanism, causal effect, or universal information ceiling.

NEXT ACTION

Execute only the supported measurement/model action, then reassess the updated substrate.

This browser demo illustrates the public controller contract. It does not run protected NPIS, OptiCeil, TotemicAI, Acquire, or controller-policy estimators.

Validation & data provenance

TopolAI’s action states are demonstrated here using separately validated component outputs; the heterogeneous validation cohorts are reported separately rather than pooled.

NPIS direct cohorts56,199 individuals · 408,014 longitudinal states across ADNI, PPMI, PRO-ACT ALS, HRS, and Add Health
OptiCeil imaging + sensorCASCADE: 914 segments / 312 neurons / 146,962 samples; BUT PPG: 82,966 samples / 3,840 recordings / 38 subjects
TotemicAI AMLGSE221578 · 3 held-out patient response fields · 39,590 perturbation-response observations
Acquire ALS / COPD / perturbationPRO-ACT: 8,260 participants / 70,746 transitions; COPDGene: 785 participants; GSE254742 cross-replicate dose-grid test
Boundary: these heterogeneous units are shown separately and are not summed into a single “sample size.” TopolAI coordinates evidence, recoverability, structural memory, acquisition, and reassessment; it does not turn retrospective component validation into a prospective clinical-control claim.
Dataset / validation references
  1. Rupprecht P, Carta S, Hoffmann A, et al. Nat Neurosci. 2021. doi:10.1038/s41593-021-00895-5.
  2. Atassi N, Berry J, Shui A, et al. Neurology. 2014. doi:10.1212/WNL.0000000000000951.
  3. NCBI GEO: GSE221578 and GSE254742.
  4. Regan EA, Hokanson JE, Murphy JR, et al. COPD. 2010. doi:10.3109/15412550903499522.
  5. Ewing MA. Nonparametric Information Sufficiency. Research Square. 2026. doi:10.21203/rs.3.rs-10897971/v1.
  6. Ewing MA. Intelligence Cannot Recover What the Instrument Does Not Record. Research Square. 2026. doi:10.21203/rs.3.rs-10959134/v1.
  7. Ewing MA. Information-Guided Inverse Design of Calcium-Imaging Acquisition with TopolAI. Research Square. 2026. doi:10.21203/rs.3.rs-10898326/v1.
  8. Ewing MA. Information, Not AI Model Sophistication, Limits Resolution of Disease Progression in COPDGene. Research Square. 2026. doi:10.21203/rs.3.rs-10898573/v1.